Limerick, Pa.-based Teleflex (NYSE:TFX) won FDA clearance for the latest in its line of peripheral nerve block needles, the Arrow UltraQuik.
The Arrow UltraQuik joins Teleflex’s StimuQuik and StimuQuik Echo, devices aimed at helping physicians perform nerve blocking, whether with ultrasound alone, via nerve stimulation, or through a combined approach, according to a press release.
The medical products giant earlier this month signed a 3-year contract with group purchasing organization Premier to provide hand-held laparoscopic surgical instruments.
TFX shares were fairly flat today, gaining 0.1% to trade at $74.79 as of about 1:25 p.m.